Ginkgo Bioworks Holdings Inc (NYSE:DNA)
$ 9.66 -0.56 (-5.48%) Market Cap: 587.43 Mil Enterprise Value: 367.95 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 37/100

Q4 2022 Ginkgo Bioworks Holdings Inc Earnings Call Transcript

Mar 01, 2023 / 09:30PM GMT
Release Date Price: $56 (-4.76%)
Anna Marie Wagner
Ginkgo Bioworks Holdings, Inc. - SVP of Corporate Development

Good afternoon. This is Anna Wagner, SVP of Corporate Development at Ginkgo Bioworks. As usual, I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.

We thank you for joining us and look forward to providing you with an update on the last quarter and full year '22. As a reminder, during the presentation today, we'll be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the Securities and Exchange Commission to learn more about these risks and uncertainties. We've got a packed agenda for today, but we'll follow our standard format, providing an update on our financial progress and guidance for the year while also taking the time to dig deeper on our strategic priorities. In particular, as we alluded to in our last call, today we'll be providing more information on the downstream value potential we see at Ginkgo. We'll enter the Q&A session, and we'll take questions from analysts, investors and the public. You can submit those questions

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot